Mini-Focus: Platelet Responsiveness |
Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel NonrespondersA Prospective, Randomized Study
Thomas Cuisset, MD*, ,*,
Corinne Frere, MD, PhD,
Jacques Quilici, MD*,
Pierre-Emmanuel Morange, MD, PhD,
Jean-Philippe Mouret, MD*,
Laurent Bali, MD*,
Pierre-Julien Moro, MD*,
Marc Lambert, MD*,
Marie-Christine Alessi, MD, PhD,
Jean Louis Bonnet, MD*
* Department of Cardiology, CHU Timone, Marseille, France
Inserm, U626, Faculté de Médecine, Laboratoire d'Hématologie, CHU Timone, Marseille, France
* Reprint requests and correspondence: Dr. Thomas Cuisset, CHU Timone, Cardiology, 264 rue Saint Pierre, Marseille 13385, France (Email: thomascuisset{at}voila.fr).
Objectives: The aim of this study was to assess, in clopidogrel nonresponders undergoing elective percutaneous coronary intervention (PCI), the benefit of adjusted antiplatelet therapy with glycoprotein (GP) IIb/IIIa antagonist administration during PCI for 1-month clinical outcome.
Background: Numerous biological studies have reported interindividual variability in platelet response to clopidogrel with clinical relevance, and high post-treatment platelet reactivity (adenosine diphosphate-induced aggregation >70%) has been proposed to define nonresponse to clopidogrel. These nonresponders might benefit from tailored antiplatelet therapy.
Methods: One hundred forty-nine clopidogrel nonresponders referred for elective PCI were prospectively included and randomized to "conventional group" (n = 75) or "active group" with GP IIb/IIIa antagonist (n = 74). All patients received 250-mg aspirin and 600-mg clopidogrel before PCI and platelet testing.
Results: The rate of cardiovascular events at 1 month was significantly lower in the "active group" than in the "conventional group": 19% (n = 14) versus 40% (n = 30), p = 0.006, odds ratio: 2.8; 95% confidence interval: 1.4 to 6.0. No patient in either group had post-procedural Thrombolysis In Myocardial Infarction major bleeding or required transfusions.
Conclusions: The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk.
Key Words: clopidogrel response • coronary stenting • glycoprotein IIb/IIIa antagonist
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | ADP-Ag = adenosine diphosphate-induced platelet aggregation | | CV = cardiovascular | | GP = glycoprotein | | PCI = percutaneous coronary intervention | | PPP = platelet-poor plasma | | PRP = platelet-rich plasma | | ST = stent thrombosis | | VASP = vasodilator-stimulated phosphoprotein |
|
Related Article
-
Resisting the Temptation to Oversimplify Antiplatelet Resistance
- Deepak L. Bhatt
J. Am. Coll. Cardiol. Intv. 2008 1: 660-662.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. E. Winchester, X. Wen, W. D. Brearley, K. E. Park, R. D. Anderson, and A. A. Bavry
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization: A Meta-Analysis of Randomized Trials Performed in the Era of Stents and Thienopyridines
J. Am. Coll. Cardiol.,
March 8, 2011;
57(10):
1190 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Campo, M. Valgimigli, C. Carrescia, R. Carletti, and R. Ferrari
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2010;
16(5):
591 - 593.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Gladding, L. Panattoni, M. Webster, L. Cho, and S. Ellis
Clopidogrel Pharmacogenomics: Next Steps: A Clinical Algorithm, Gene-Gene Interactions, and an Elusive Outcomes Trial
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
995 - 1000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bonello, U. S. Tantry, R. Marcucci, R. Blindt, D. J. Angiolillo, R. Becker, D. L. Bhatt, M. Cattaneo, J. P. Collet, T. Cuisset, et al.
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
J. Am. Coll. Cardiol.,
September 14, 2010;
56(12):
919 - 933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, D. R. Holmes Jr, G. J. Dehmer, S. Kaul, D. Leifer, P. T. O'Gara, and C. M. Stein
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
Circulation,
August 3, 2010;
122(5):
537 - 557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, G. J. Dehmer, S. Kaul, D. Leifer, P. T. O'Gara, and C. M. Stein
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
July 20, 2010;
56(4):
321 - 341.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mangiacapra, E. Barbato, G. Patti, L. Gatto, V. Vizzi, E. Ricottini, A. D'Ambrosio, W. Wijns, and G. Di Sciascio
Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv.,
March 1, 2010;
3(3):
318 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
How Should Clopidogrel Nonresponders Be Treated?
Journal Watch Cardiology,
January 21, 2009;
2009(121):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
D. L. Bhatt
Resisting the Temptation to Oversimplify Antiplatelet Resistance
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
660 - 662.
[Full Text]
[PDF]
|
|
|
|
